Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy

Agnieszka K. Witkiewicz, Mathew C. Casimiro, Abhijit Dasgupta, Isabelle Mercier, Chenguang Wang, Gloria Bonuccelli, Jean François Jasmin, Philippe G. Frank, Richard G. Pestell, Celina G. Kleer, Federica Sotgia, Michael P. Lisanti

    Research output: Contribution to journalArticlepeer-review


    Here, we discuss recent evidence that an absence of stromal Cav-1 expression in human breast cancers is a powerful single independent predictor of early disease recurrence, metastasis and poor clinical outcome. These findings have now been validated in two independent patient populations. Importantly, the predictive value of stromal Cav-1 is independent of epithelial marker status, making stromal Cav-1 a new "universal" or "widely- applicable" breast cancer prognostic marker. We propose based on the expression of stromal Cav-1, that breast cancer patients could be stratified into high-risk and low-risk groups. High-risk patients showing an absence of stromal Cav-1 should be offered more aggressive therapies, such as anti-angiogenic approaches, in addition to the standard therapy regimens. Mechanistically, loss of stromal Cav-1 is a surrogate biomarker for increased cell cycle progression, growth factor secretion, "stemness", and angiogenic potential in the tumor microenvironment. Since almost all cancers develop within the context of a stromal microenvironment, this new stromal classification system may be broadly applicable to other epithelial and non-epithelial cancer subtypes, as well as "pre-malignant" lesions (carcinoma in situ). ©2009 Landes Bioscience.
    Original languageEnglish
    Pages (from-to)1654-1658
    Number of pages4
    JournalCell Cycle
    Issue number11
    Publication statusPublished - 1 Jun 2009


    • Biomarkers
    • Breast cancer
    • Cancer-associated fibroblasts
    • Caveolin-1
    • Prognosis
    • Stroma
    • Treatment stratification


    Dive into the research topics of 'Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy'. Together they form a unique fingerprint.

    Cite this